ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
- Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025.
- Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025.
- Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025.
- Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025.
- Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.
- Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026.
Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram,LinkedIn, and X.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
March 31, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $241,289 $186,897
Marketable investments 374,371 357,919
Accounts receivable, net 183,295 190,021
Inventories 438,539 431,549
Prepaid expenses and other current assets 37,912 50,298
Total current assets 1,275,406 1,216,684
Property and equipment, net 134,059 117,436
Operating lease right-of-use assets 170,273 173,587
Finance lease right-of-use assets 25,209 25,972
Intangible assets, net 5,946 6,186
Goodwill 166,589 166,750
Deferred taxes 79,972 79,188
Other non-current assets 40,984 40,716
Total assets $1,898,438 $1,826,519
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $43,658 $34,736
Accrued liabilities 151,543 132,163
Current operating lease liabilities 14,144 13,841
Current finance lease liabilities 2,386 2,393
Total current liabilities 211,731 183,133
Non-current operating lease liabilities 179,424 182,751
Non-current finance lease liabilities 20,221 20,714
Other non-current liabilities 13,250 12,318
Total liabilities 424,626 398,916
Stockholders' equity:
Common stock 39 39
Additional paid-in capital 1,201,423 1,185,525
Accumulated other comprehensive income 2,075 4,348
Retained earnings 270,275 237,691
Total stockholders' equity 1,473,812 1,427,603
Total liabilities and stockholders' equity $1,898,438 $1,826,519
Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended March 31,
2026 2025
Revenue $374,758 $324,140
Cost of revenue 121,347 108,257
Gross profit 253,411 215,883
Operating expenses:
Research and development 22,382 22,077
Sales, general and administrative 192,795 153,456
Total operating expenses 215,177 175,533
Income from operations 38,234 40,350
Interest and other income, net 3,454 3,508
Income before income taxes 41,688 43,858
Provision for income taxes 9,104 4,635
Net income $32,584 $39,223
Net income per share:
Basic $0.83 $1.02
Diluted $0.82 $1.00
Weighted average shares outstanding:
Basic 39,275,424 38,562,191
Diluted 39,543,780 39,163,428
Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions
(unaudited)
(in thousands, except for percentages)
Three Months Ended March 31, Change
2026 2025
$ %
United
States $296,387 $256,860 $39,527 15.4 %
International 78,371 67,280 11,091 16.5 %
Total $374,758 $324,140 $50,618 15.6 %
Penumbra, Inc.
Reconciliation of Revenue Growth by Product Categories
(unaudited)
(in thousands, except for percentages)
Three Months Ended March 31, Change
2026 2025
$ %
Thrombectomy $253,917 $226,544 $27,373 12.1 %
Embolization and Access 120,841 97,596 23,245 23.8 %
Total $374,758 $324,140 $50,618 15.6 %
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2026-financial-results-302764359.html
SOURCE Penumbra, Inc.
